ZP purchased the technology assets of Sarissa Biomedical in 2021 when Sarissa Biomedical went into liquidation. The Sarissa Biomedical sensor technologies, including the capillary electrodes, are now available from ZP.
Sarissa produced novel biosensors for measuring purines during in vitro and in vivo studies for research and diagnostic use in their SMARTChip.
HISTORY OF SARISSA BIOMEDICAL
Sarissa Biomedical was formed in November 2002 as a spin-out from Warwick University, specialising in the development and production of novel biosensors for the measurement of neuroactive chemicals. Sarissa developed biosensors for the following analytes: ATP, Adenosine, Inosine, Hypoxanthine, Acetylcholine, Choline, Glutamate, Glucose, Lactate and D-serine. Sarissa’s sensors are ideal for real-time recordings in a variety of tissues in vitro and in vivo and can be used in combination with electrophysiological techniques (extracellular recording, patch clamp recording) as well as fluorescent imaging methods.
PROFILE
Sarissa was developing a range of minimally invasive, microelectrode electrochemical sensors for the measurement of the purines and other neurochemicals, as indicators of neurological activity / disorders and has a product design platform that offeed exquisite sensitivity, coupled with a broad linear activity range and high levels of accuracy and reproducibility. These biosensors were designed for in vitro and in vivo studies for research and diagnostic applications.
Crucial to the Sarissa’s highly differentiated technology were the unique methods by which active enzyme-based layers are deposited onto the surface of the sensor. In the case of the ATP sensor (sarissaprobe®-ATP) the enzyme matrix includes kinase and oxidase, deposited onto the surface of a Pt/Ir microelectrode.
- Website
#ZP
#biosensors
